Ruxolitinib, an inhibitor of the Janus kinase 2 (JAK2)/signal transducer and activator of the transcription 3 (STAT3) signaling pathway, and LINC00691 knockdown substantially eliminated the effects on NFs in exosome-containing GC cell supernatants. The gene discussed is JAK2; the disease is gastric cancer.